Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs

4 Jun 2021

Abstract excerpt

Nucleoside-modified messenger RNA (mRNA)-lipid nanoparticles (LNPs) are the basis for the first two EUA (Emergency Use Authorization) COVID-19 vaccines. The use of nucleoside-modified mRNA as a pharmacological agent opens immense opportunities for therapeutic, prophylactic and diagnostic molecular interventions. In particular, mRNA-based drugs may specifically modulate immune cells, such as T lymphocytes, for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immunotherapy and Immune Responses
Share to RNA Interference and Gene Delivery
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34091054
DOI: 10.1016/j.ymthe.2021.06.004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPsPMID 34091054Read ↗

In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cellsSemantic proximity Read ↗

Rapid receptor internalization potentiates CD7-targeted lipid nanoparticles for efficient mRNA delivery to T cells and <i>in vivo</i> CAR T-cell engineeringSemantic proximity Read ↗

From structural design to delivery: mRNA therapeutics for cancer immunotherapySemantic proximity Read ↗

An inherent T cell-activating mRNA delivery platform for <i>in vivo</i> CAR T generationSemantic proximity Read ↗

Systemic trafficking of mRNA lipid nanoparticle vaccine following intramuscular injection generates potent tissue-specific T cell responseSemantic proximity Read ↗

mRNA vaccines as cancer therapiesSemantic proximity Read ↗

The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell ImmunotherapySemantic proximity Read ↗

mRNA‐based chimeric antigen receptor T cell therapy: Basic principles, recent advances and future directionsSemantic proximity Read ↗

Recent Advancements in mRNA Vaccines: From Target Selection to Delivery SystemsSemantic proximity Read ↗

Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell GenerationSemantic proximity Read ↗

mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trendsSemantic proximity Read ↗

Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imagingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.